Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intervention with carbocysteine and low-dose theophylline in Chinese patients with early-stage COPD
ChiCTR1800016712Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of carbocisteine and theophylline in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Trough FEV1 at 12 months from baseline, Peak FEV1 at 12 months from baseline and 1 more. Started Jul 2018; status: recruiting.
02
Drugs
carbocisteinetheophylline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR1800016712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016712.